Healthcare entity
regulation is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention ANKTIVA, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.9 for the broader beat in this window.
Last mentioned: Mar 25, 2026
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 0 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 2 tracked stories. Of the tracked stories, 1 of 2 also mention ANKTIVA, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.9 for the broader beat in this window. Their average consequence score of 7 runs above the beat's 6.1 for that window. This profile follows 2 Healthcare stories mentioning Patrick Soon-Shiong across the period from March 24, 2026 to March 25, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 55 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Patrick Soon-Shiong. Shared-story counts are live from our verified record — not editorial picks.
Expected Regional Launch
Anticipated availability of ANKTIVA in Macau oncology centers.
Macau SAR Approval
Macau Health Bureau grants regulatory clearance for ANKTIVA.
FDA Warning Issued
The FDA flags the podcast statements as misleading and issues an Untitled Letter to ImmunityBio.
Podcast Appearance
Patrick Soon-Shiong discusses the drug's potential on a high-profile industry podcast.
U.S. Commercial Launch
ImmunityBio begins commercial distribution of ANKTIVA in the U.S.
Initial FDA Approval
Anktiva (N-803) receives FDA approval for BCG-unresponsive NMIBC.
ImmunityBio Inc. has received regulatory approval for its flagship immunotherapy, ANKTIVA, in the Macau Special Administrative Region of China. This milestone marks the first international expansion for the IL-15 superagonist following its 2024 U.S. FDA approval, positioning the company to tap into the significant oncology market in the Greater Bay Area.
Source: finance.yahoo.com · insidermonkey.com
The FDA has issued a formal warning to ImmunityBio and its founder, Patrick Soon-Shiong, regarding misleading public statements about the company's bladder cancer drug. The regulator cited claims made during a podcast that suggested broader efficacy than currently approved, raising concerns about off-label promotion.
Patrick Soon-Shiong is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
